ICVTS Click here for other ICVTS advertising opportunities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Interact CardioVasc Thorac Surg 2006;5:58-59. doi:10.1510/icvts.2005.123430
© 2006 European Association of Cardio-Thoracic Surgery
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Tom Treasure
Carol Tan
David Waller
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Treasure, T.
Right arrow Articles by Waller, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Treasure, T.
Right arrow Articles by Waller, D.
Related Collections
Right arrow Pleura

Protocol - Thoracic general

The MARS trial: mesothelioma and radical surgery

Tom Treasurea,*, Carol Tana, Loïc Lang-Lazdunskia and David Wallerb

a Thoracic Unit, Guy's Hospital, SE1 9RT, London, UK
b Glenfield Hospital, Leicester, UK

*Corresponding author. Tel.: +44-79-57-16-87-54.

E-mail address: tom.treasure{at}ukgateway.net (T. Treasure).

The increasing incidence of malignant pleural mesothelioma has demanded the attention of thoracic surgeons worldwide. Can radical surgery cure mesothelioma or add usefully to the length and quality of life for its victims? The MARS (mesothelioma and radical surgery) trial is open and recruiting in Britain. If the trial proves feasible we will seek to make an international study.

Key Words: Malignant (pleural) mesothelioma; Extrapleural pneumonectomy; Randomized controlled trial; Trimodality cancer treatment




This article has been cited by other articles:


Home page
 ChestHome page
M. Ray and H. L. Kindler
Malignant Pleural Mesothelioma: An Update on Biomarkers and Treatment
Chest, September 1, 2009; 136(3): 888 - 896.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
T. Treasure
Pulmonary metastasectomy for colorectal cancer: weak evidence and no randomised trials
Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 300 - 302.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Lucchi, A. Chella, F. Melfi, P. Dini, M. Ambrogi, L. Fino, G. Fontanini, and A. Mussi
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma
Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 529 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
T. Treasure
The evidence on which to base practice: different tools for different times
Eur. J. Cardiothorac. Surg., December 1, 2006; 30(6): 819 - 824.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 European Association for Cardio-thoracic Surgery